Vtv Therapeutics INC 10-Q quarterly reports

vTv Therapeutics Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting $36.8 million in revenue driven by licensing agreements, but also significant operating losses and a substantial accumulated deficit.

vTv Therapeutics Inc. reported a significant revenue increase in Q1 2026 driven by an upfront payment from Newsoara Biopharma, while research and development expenses also rose.

vTv Therapeutics Inc. reported an increased net loss for Q3 2025 but significantly strengthened its cash position through a recent private placement, removing prior going concern doubts.

vTv Therapeutics Inc. reported an increased net loss in the second quarter of 2025, driven by higher research and development expenses, as it reinitiates its pivotal Phase 3 CATT1 trial for cadisegliatin in Type 1 diabetes.

vTv Therapeutics announces its Q1 2025 financial results and the reinitiation of the CATT1 trial for cadisegliatin following the lifting of a clinical hold by the FDA.

vTv Therapeutics reported its third quarter 2024 financial results, highlighting a revenue of $1 million and a net loss of $4.783 million, while also providing an update on its clinical programs and recent corporate activities.

vTv Therapeutics reported its second quarter 2024 financial results, highlighting a revenue of $1 million and a net loss of $10.045 million, while also announcing a clinical hold on its cadisegliatin program.

vTv Therapeutics reported a net loss of $4.9 million for the first quarter of 2024, alongside a significant increase in cash reserves due to a recent private placement.